Lori Hu
Managing Director at Vertex Ventures HC
San Francisco Bay Area
Overview
Work Experience
Managing Director
2015 - Current
Vertex Ventures HC (www.vertexventureshc.com) is part of a global venture fund network under Vertex Venture Holdings, a subsidiary of Temasek Holdings, with offices in San Francisco and Boston. Vertex Ventures HC invests globally focusing on biotech and medical technologies with $550M assets under management.
Board Observer
2023
Board Director
2022
SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound.
Raised $60,750,000.00 from Eli Lilly & Company Foundation, Medical Excellence Capital, ARCH Venture Partners, Johnson & Johnson Innovation – JJDC, Foothill Ventures, Alexandria Venture Investments, Wilson Sonsini Goodrich & Rosati, Formic Ventures, Illumina Ventures and Lifespan Investments.
Board Director
2018
Glycan-mediated immune regulation to treat cancer and inflammatory diseases
Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.
Raised $147,600,000.00 from Takeda Ventures, Pfizer Venture Investments, Matrix Capital Management, Vertex Ventures HC, AbbVie, Surveyor Capital and SR One.
Board Director
2022
NK cell therapy
Board Director
2021
Miniaturized neuromodulation
NeuSpera Medical is a manufacturing firm that designs, manufactures, and sells implantable neuromodulation medical devices.
Raised $134,888,888.00 from Action Potential Venture Capital, Treo Ventures, Windham Venture Partners, Vertex Ventures HC and Olympus.
Board Director
2019 - 2024
Clinical-stage targeted oncology company (NASDAQ: ELEV)
Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.
Raised $197,500,000.00 from K2 HealthVentures.
Board Observer
2015 - 2022
Board Director
2018 - 2020
Precision neuroscience co (now part of Neumora)
VC Associate
2014 - 2015
Evaluate early-stage healthcare and biotech opportunities for SR One, GlaxoSmithKline's independent corporate healthcare venture capital fund
SR One is the corporate venture capital arm of GlaxoSmithKline.